KUROS BIOSCIENCESKUROS BIOSCIENCESKUROS BIOSCIENCES

KUROS BIOSCIENCES

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪799.36 M‬CHF
−0.243CHF
‪−13.73 M‬CHF
‪33.56 M‬CHF
‪24.87 M‬
Beta (1Y)
0.91
Employees (FY)
5
Change (1Y)
−1 −16.67%
Revenue / Employee (1Y)
‪7.97 M‬CHF
Net income / Employee (1Y)
‪−3.26 M‬CHF

About KUROS N


CEO
Christopher T. Fair
Headquarters
Schlieren
Founded
2000
ISIN
CH0325814116
FIGI
BBG006M6Z786
Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of YTSN is 23.352 CHF — it has increased by 3.73% in the past 24 hours. Watch KUROS BIOSCIENCES stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange KUROS BIOSCIENCES stocks are traded under the ticker YTSN.
YTSN stock has fallen by −22.29% compared to the previous week, the month change is a −8.92% fall, over the last year KUROS BIOSCIENCES has showed a 515.01% increase.
We've gathered analysts' opinions on KUROS BIOSCIENCES future price: according to them, YTSN price has a max estimate of 19.00 CHF and a min estimate of 19.00 CHF. Watch YTSN chart and read a more detailed KUROS BIOSCIENCES stock forecast: see what analysts think of KUROS BIOSCIENCES and suggest that you do with its stocks.
YTSN reached its all-time high on Nov 14, 2024 with the price of 31.797 CHF, and its all-time low was 1.235 CHF and was reached on Apr 3, 2023. View more price dynamics on YTSN chart.
See other stocks reaching their highest and lowest prices.
YTSN stock is 3.59% volatile and has beta coefficient of 0.91. Track KUROS BIOSCIENCES stock price on the chart and check out the list of the most volatile stocks — is KUROS BIOSCIENCES there?
Today KUROS BIOSCIENCES has the market capitalization of ‪841.63 M‬, it has decreased by −22.43% over the last week.
Yes, you can track KUROS BIOSCIENCES financials in yearly and quarterly reports right on TradingView.
KUROS BIOSCIENCES is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
KUROS BIOSCIENCES revenue for the last half-year amounts to ‪31.80 M‬ CHF, despite the estimated figure of ‪30.00 M‬ CHF. In the next half-year revenue is expected to reach ‪45.30 M‬ CHF.
YTSN net income for the last half-year is ‪−211.00 K‬ CHF, while the previous report showed ‪−8.68 M‬ CHF of net income which accounts for 97.57% change. Track more KUROS BIOSCIENCES financial stats to get the full picture.
No, YTSN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 23, 2024, the company has 5.00 employees. See our rating of the largest employees — is KUROS BIOSCIENCES on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KUROS BIOSCIENCES EBITDA is ‪−2.30 M‬ CHF, and current EBITDA margin is −18.33%. See more stats in KUROS BIOSCIENCES financial statements.
Like other stocks, YTSN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KUROS BIOSCIENCES stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So KUROS BIOSCIENCES technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating KUROS BIOSCIENCES stock shows the neutral signal. See more of KUROS BIOSCIENCES technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.